QualityDipStocks / Health Care · Medical Electronics
Koninklijke Philips N.V. NY Registry Shares PHG
Outside our quality screen, so we don’t track its dips. It’s 18% below its 52-week high.
Outside our quality screen. No fair value estimate for now: its filings are too old.
- Fair value est.
- n/a
- Market Value
- —
- Off 52-wk high
- −18%
- Risk vs market
- Below marketbeta 0.81
4 bullish · 5 bearish See why
Key levels
Every level vs today’s $26.92
- 52-wk lowlowest close, 1 year$23.81−11.6%
- PriceFri Oct 30 close$26.92you are here
- 52-wk highhighest close, 1 year$32.91+22.3%
Fair value estimate
No estimate for PHG: Latest cash-flow data in SEC XBRL ends 2021-12-31, too old to use. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much PHG moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves a bit less than the market, and its own price swings are 2.2× the S&P 500’s.
- Beta vs S&P 500
- 0.81
- Volatility
- 28% vs 13% SPY
- Correlation SPY
- 0.37
- Correlation QQQ
- 0.21
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
ProfitabilityOperating margin widened to 8.0% in FY2025 from −0.6% in FY2023 (SEC filings).
Balance sheetNet cash of $1.8B: cash and short-term investments exceed debt (Dec 31, 2025).
ProfitabilityGross margin widened to 45.2% in FY2025 from 41.0% in FY2023 (SEC filings).
ValuationEV/EBITDA of 8.7×: modest for what the business earns before interest, tax and depreciation.
Top bearish points 5 of 5
Balance sheetDebt rose 76% to $1.3B from FY2023 to FY2025.
GrowthSales grew only 0.0% a year from FY2022 to FY2025.
GrowthSales fell 1.0% over the last 12 months, below the 8.6% median for the 101 Health Care companies we cover.
ProfitabilityReturn on equity is only 8% over the last 12 months.
QualityDoesn’t pass our quality screen: ROE under 12% and ROIC under 10%.
Who’s talking about it
Notable investors, executives, analysts and public figures on Koninklijke Philips N.V. NY Registry Shares in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Health Care
All fundamentals
P/E 26.6 · ROE 8% · Sales −1%
Valuation
- P/E
- 26.6×Health Care median 29.2×
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- 8.7×
- Price / sales
- 1.33×
- Price / book
- 2.17×
- Market cap
- $26.7Blisted
- Enterprise value
- $24.9B
Growth
- Revenue, 12 months
- $20.0B
- Sales growth, 12 months
- −1.0%vs the 12 months before
- Sales growth, 3 yrs
- +0.0%/yrfrom FY2022
- Diluted EPS, 12 months
- $0.93
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- $1.0B
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 45.2%
- Operating margin
- 8.0%
- Net margin
- 5.0%
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- 8%
- Return on invested capital
- 12%
Balance sheet
- Cash & short-term inv.
- $3.1B
- Total debt
- $1.3B
- Net cash
- $1.8B
- Debt / equity
- 0.11×
- Interest coverage
- 4.9×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 1.39%$370M paid
- Payout ratio
- 37%
- Buybacks, 12 months
- $0
- Share count, 1 year
- n/ano quarterly diluted share count
- Stock-based comp
- n/anot reported in its SEC filings
Trailing 12 months to Dec 31, 2025; balance sheet at Dec 31, 2025. From Koninklijke Philips N.V. NY Registry Shares’s SEC filings, reported in EUR and converted to US dollars. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
FCF value $40.58
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 65 · 5 days +0.1%
The business
FCF $1.6B · Sales 0%
- Free cash flow, 12 months$1.6B
- Free-cash-flow yield6.0%
- Free-cash-flow margin9%
- Gross margin46%
- Operating margin10%
- Return on invested capital7%
- Return on equity10%
- Sales growth (latest quarter vs year-ago quarter)0%
- Net debt / EBITDA1.9×
Next report
Nov 3
- DateTue Nov 3, before the open
- Consensus EPS$0.37
- Year-ago EPS$0.37
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
PHG is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.